High plasma fibrinogen level is associated with poor clinical outcome in DIC patients

American Journal of Hematology

Volumn 72, Issue 1, 2003, Pages 1-7

  Wada, Hideo ^a   Mori, Yoshitaka ^b   Okabayashi, Kazuhiro ^a   Gabazza, Esteban C ^a   Kushiya, Fumihiko ^a   Watanabe, Masato ^a   Nishikawa, Masakatsu ^a   Shiku, Hiroshi ^a   Nobori, Tsutomu ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mie Red Cross Blood Center   (Japan)

Author keywords

DIC; Fibrinogen; Hypofibrinolysis; Organ failure; Outcome

Indexed keywords

ANTIPLASMIN; FIBRINOGEN; FRUCTOSE BISPHOSPHATE; PLASMA PROTEIN; PLASMIN INHIBITOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANALYSIS; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL STANDARD UNIT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; ANTITHROMBIN III; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; INFECTION; INTERLEUKIN-1; INTERLEUKIN-6; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEOPLASMS; PEPTIDE HYDROLASES; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET COUNT; PROGNOSIS; THROMBOMODULIN; THROMBOPLASTIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037222911     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10249     Document Type: Article

References (26)

1. Bick RL. Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1998;14:299-338.
2. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58-98.
3. Kobayashi N, Maegawa K, Takada M, Tanaka H, Gonnmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987;49:265-275.
4. Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi A, Mori Y, Deguchi K, Shirakawa S, Suzuki K. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994;43:265-275.
5. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. The Mie DIC Study Group. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995:73:848-852.
6. Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with enzyme-linked immunosorbent assay. Thromb Haemost 1987;59:101-106.
7. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α2 plasmin inhibitor. Blood 1987;69:446-452.
8. Wada H, Wakiya Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;51:255-260.
9. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M. Clinical evaluation of low-molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC): A multicenter cooperative double-blind trial in comparison with heparin. Thromb Res 1993;72:495-500.
10. Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY [ethyl p-(6-guanidino-hexanoxyloxy)benzoate]methanesulfonate as a serine protease inhibitor, II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1980;24:455-452.
11. Brauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985;39:81-89.
12. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Rodriguez AL, Steingrub JS, Garber GE, Helterbrand JD, Ely W, Fisher CJ Jr, for The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
13. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-721.
14. Members of the American College of Chest Physicians/Society of Critical care Medicine, Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
15. Beal A, Cerra FB. Multiple organ failure syndrome in the 1990s: Systemic inflammatory response and organ dysfunction. J Am Med Assoc 1994;271:226-233.
16. Wada H, Tomeoku M, Deguchi A, Suzuki H, Mori Y, Ito M, Deguchi K, Shirakawa S. Anticoagulant activity in cell homogenate of adult T cell leukemia. Thromb Haemost 1988;59:197-201.
17. Ikuma H, Wada H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Nishikawa M, Onoda K, Yamada N, Ohta T, Nishioka J, Nobori T, Gabazza EC, Sakuragawa N, Shiku H. Hemostatic markers in Japanese patients undergoing anticoagulant therapy under thrombo-test monitoring. Blood Coagul Fibrinolysis 1999;10:429-434.
18. Wada H, Gabazza E, Nakasaki T, Shimura M, Hiyoyama K, Deguchi K, Nishikawa M, Sakuragawa N, Shiku H. Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers. Semin Thromb Hemost 2000;26:17-21.
19. Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, Nishikawa M, Nakano M, Kumeda K, Kaneko T, Nakamura S, Shiku H. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998;58:189-194.
20. Wada H, Ohiwa M. Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992;39:20-24.
21. Schorer AE, Kaplan ME, Rao GHR, Moldow CF. Interleukin-1 stimulated endothelial tissue factor production and expression by a prostaglandin-independent mechanism. Thromb Haemost 1987;56:256-259.
22. Bevilacqua MP, Prober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537.
23. Rickles FR, Pick PD, Van Why M. Structural features of S. typhimurium lipopolysaccharide required for activation of monocyte tissue factor. J Clin Invest 1977;59:1188-1195.
24. Sprengers ED, Kluft C. Plasminogen activator inhibitor. Blood 1987; 69:381.
25. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EK. Plasminogen activator inhibitor I: A new prognostic marker in septic shock. Thromb Haemost 1989;61:459.
26. Coluci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75:818.